ELAB
Price
$2.67
Change
-$0.04 (-1.48%)
Updated
Oct 22 closing price
Capitalization
2.16M
22 days until earnings call
Intraday BUY SELL Signals
ERNA
Price
$2.08
Change
-$0.03 (-1.42%)
Updated
Oct 22 closing price
Capitalization
2.42M
15 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ELAB vs ERNA

ELAB vs ERNA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ELAB vs. ERNA commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAB is a Hold and ERNA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ELAB with price predictions
Oct 22, 2026

ELAB in +4.69% Uptrend, rising for three consecutive days on October 20, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ELAB advanced for three days, in 76 of 91 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for ELAB just turned positive on September 21, 2026. Looking at past instances where ELAB's MACD turned positive, the stock continued to rise in 11 of 14 cases over the following month. The odds of a continued upward trend are 79%.

ELAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ELAB as a result. In 45 of 46 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for ELAB entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.129) is normal, around the industry mean (2.973). P/E Ratio (-0.001) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.250) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. ELAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for ERNA with price predictions
Oct 22, 2026

ERNA in -7.37% downward trend, falling for three consecutive days on October 22, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ERNA declined for three days, in 377 of 388 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for ERNA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ERNA's RSI Indicator exited the oversold zone, 39 of 51 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 64 cases where ERNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.

The Moving Average Convergence Divergence (MACD) for ERNA just turned positive on October 21, 2026. Looking at past instances where ERNA's MACD turned positive, the stock continued to rise in 35 of 41 cases over the following month. The odds of a continued upward trend are 85%.

Following a +10.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where ERNA advanced for three days, in 157 of 193 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

ERNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.757) is normal, around the industry mean (2.973). P/E Ratio (-5.061) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1250.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. ERNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ERNA: Fundamental Ratings
ERNA
OUTLOOK RATING
1..100
77
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
94
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ELABERNA
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 15 days ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ELAB: $2.67 vs. ERNA: $2.08)
Brand notoriety: ELAB and ERNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELAB: 10% vs. ERNA: 42%
Market capitalization -- ELAB: $2.16M vs. ERNA: $2.42M
ELAB [@Biotechnology] is valued at $2.16M. ERNA’s [@Biotechnology] market capitalization is $2.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAB’s FA Score shows that 0 FA rating(s) are green while ERNA’s FA Score has 0 green FA rating(s).

  • ELAB’s FA Score: 0 green, 5 red.
  • ERNA’s FA Score: 0 green, 5 red.
According to our system of comparison, ELAB is a better buy in the long-term than ERNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAB’s TA Score shows that 4 TA indicator(s) are bullish while ERNA’s TA Score has 5 bullish TA indicator(s).

  • ELAB’s TA Score: 4 bullish, 3 bearish.
  • ERNA’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, ERNA is a better buy in the short-term than ELAB.

Price Growth

ELAB (@Biotechnology) experienced а -10.85% price change this week, while ERNA (@Biotechnology) price change was -4.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

ELAB is expected to report earnings on Nov 13, 2026.

ERNA is expected to report earnings on Nov 06, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ELAB
Daily Signal:
Gain/Loss:
ERNA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ELAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELAB has been loosely correlated with LPCN. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAB jumps, then LPCN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAB
1D Price
Change %
ELAB100%
-1.48%
LPCN - ELAB
42%
Loosely correlated
-8.75%
LXRX - ELAB
25%
Poorly correlated
-4.49%
HURA - ELAB
25%
Poorly correlated
-3.60%
ERNA - ELAB
24%
Poorly correlated
-1.66%
MTNB - ELAB
24%
Poorly correlated
+12.50%
More

ERNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERNA has been loosely correlated with MDGL. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ERNA jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERNA
1D Price
Change %
ERNA100%
-1.66%
MDGL - ERNA
36%
Loosely correlated
-1.01%
IBIO - ERNA
32%
Poorly correlated
-6.67%
SMMT - ERNA
31%
Poorly correlated
-1.77%
CYTK - ERNA
29%
Poorly correlated
-0.84%
AMRN - ERNA
28%
Poorly correlated
+0.78%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MICC19.390.44
+2.32%
The Magnum Ice Cream Company NV
LGCL1.630.02
+1.24%
Lucas GC Limited
RGNX7.17N/A
N/A
REGENXBIO
FTRE23.92-0.14
-0.58%
Fortrea Holdings
NDLS11.90-0.63
-5.03%
Noodles & Co